Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01739400 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT01739400 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 217 participants.
The verdict
NCT01739400, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
Interventions
- DRUG Macitentan 10 mg tablet, once daily.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2013-09-10 |
| Est. Completion | 2018-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01739400
The ClinicalTrials.gov registry entry for NCT01739400 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Macitentan 10 mg tablet, once daily. is the first listed.
NCT01739400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01739400 about?
NCT01739400 is a clinical study titled "Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome". Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
What is the current status of trial NCT01739400?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2013-09-10. Estimated completion is 2018-01-12.
What interventions are being tested in trial NCT01739400?
The interventions under investigation include: Macitentan 10 mg tablet, once daily. (DRUG).
Who is sponsoring clinical trial NCT01739400?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.